Jenny and the rest of the Genoa Ventures team have been instrumental in providing a robust foundation for InterVenn. Their insights, network and boundless support have been instrumental in taking a poorly understood but incredibly powerful glycoproteomic approach into a game changing clinical tool that will affect the world.
Aldo Carrascoso | CEO InterVenn